Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05844527Phase 2Completed

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Role: lead

NCT06315608Phase 2Not Yet Recruiting

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

Role: lead

NCT06308926Phase 2Not Yet Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Role: lead

NCT06307522Phase 2Not Yet Recruiting

MRG-001 in Patients With Alcoholic Hepatitis

Role: lead

NCT04646603Phase 2Unknown

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Role: lead

All 5 trials loaded